These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 16215673

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 4. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
    Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H.
    Oncogene; 2008 Mar 27; 27(14):2055-63. PubMed ID: 17998943
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
    Yoo J, Park SS, Lee YJ.
    J Cell Biochem; 2008 Aug 01; 104(5):1636-46. PubMed ID: 18404675
    [Abstract] [Full Text] [Related]

  • 9. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X, Li H.
    Cancer Lett; 2004 Jul 08; 210(1):63-71. PubMed ID: 15172122
    [Abstract] [Full Text] [Related]

  • 10. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
    Ray S, Shyam S, Fraizer GC, Almasan A.
    Mol Cancer Ther; 2007 Apr 08; 6(4):1368-78. PubMed ID: 17431115
    [Abstract] [Full Text] [Related]

  • 11. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 08; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 12. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q, Luo X, Huang Y, Sheikh MS.
    Oncogene; 2002 Sep 05; 21(39):6032-40. PubMed ID: 12203115
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM.
    Int J Cancer; 2002 Jun 01; 99(4):491-504. PubMed ID: 11992538
    [Abstract] [Full Text] [Related]

  • 14. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 15. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
    Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, Shamimi-Noori SM, Maxhimer JB, Schrump DS, Nguyen DM.
    Apoptosis; 2007 Jan 07; 12(1):55-71. PubMed ID: 17136498
    [Abstract] [Full Text] [Related]

  • 16. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.
    Gong B, Almasan A.
    Cancer Res; 2000 Oct 15; 60(20):5754-60. PubMed ID: 11059770
    [Abstract] [Full Text] [Related]

  • 17. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
    Hao JH, Yu M, Liu FT, Newland AC, Jia L.
    Cancer Res; 2004 May 15; 64(10):3607-16. PubMed ID: 15150119
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
    Tsai WS, Yeow WS, Chua A, Reddy RM, Nguyen DM, Schrump DS, Nguyen DM.
    Mol Cancer Ther; 2006 Dec 15; 5(12):2977-90. PubMed ID: 17172403
    [Abstract] [Full Text] [Related]

  • 19. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
    Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC.
    Cell Death Differ; 2004 Aug 15; 11(8):915-23. PubMed ID: 15118763
    [Abstract] [Full Text] [Related]

  • 20. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C, King DL, Norris JS.
    Cancer Gene Ther; 2002 Feb 15; 9(2):164-72. PubMed ID: 11857034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.